NHL患者血清IL-21的表达及临床意义

发布时间：2018-06-26 22:40

  本文选题：非霍奇金淋巴瘤 + 白细胞介素21　； 参考：《遵义医学院》2017年硕士论文

【摘要】：目的:检测非霍奇金淋巴瘤(NHL)患者血清中白细胞介素21(IL-21)的表达水平,探索IL-21与NHL的发病及预后的相关性。方法:选择2015年12月至2016年12月遵义医学院附属医院收治的36例NHL患者作为研究对象(初诊NHL患者20例,化疗后NHL患者16例),13例健康体检者作为正常对照组,应用酶联免疫吸附试验(ELISA)测定NHL患者及对照组血清IL-21水平,对比初诊NHL患者血清IL-21水平在年龄、性别、分期、分组、有无结外浸润等临床因素的差别,分析治疗前后NHL患者血清IL-21水平的变化,探讨血清IL-21水平在NHL患者中表达及临床意义。结果:1)NHL患者血清IL-21水平(200.75±58.91ng/L)明显低于对照组(420.91±132.56ng/L),差异具有统计学意义(P0.05);2)初诊NHL处于III期和IV期患者血清IL-21水平(153.77±25.97ng/L)显著低于I期和II期患者血清IL-21水平(223.87±35.36ng/L),差异具有统计学意义(P0.05);初诊NHL患者中有全身症状者血清IL-21水平(141.15±17.95ng/L)低于无全身症状者血清IL-21水平(208.46±33.50ng/L),差异具有统计学意义(P0.05);初诊NHL患者中有结外浸润者血清IL-21水平(143.94±19.38ng/L)明显低于无结外浸润者血清IL-21水平(212.53±32.80ng/L),差异具有统计学意义(P0.05);初诊NHL患者中60岁者血清IL-21水平(168.13±52.02ng/L)与≤60岁者血清IL-21水平(177.03±41.86ng/L)无明显差异(P0.05);初诊NHL中男性患者血清IL-21水平(186.99±41.09ng/L)与女性患者血清IL-21水平(156.52±42.47ng/L)无明显差异(P0.05);初诊B细胞型NHL患者血清IL-21水平(176.70±40.46ng/L)与初诊T细胞型NHL患者血清IL-21水平(167.21±60.02ng/L)无明显差异(P0.05);3)20例初诊NHL患者中有12例经治疗后取得缓解或部分缓解,治疗前患者血清IL-21水平为(162.63±38.75ng/L),治疗缓解后患者血清IL-21水平为(264.45±43.89ng/L),治疗前、治疗缓解后NHL患者血清IL-21水平比较差异具有统计学意义(P0.05)。结论:1)IL-21表达水平下调可能与NHL的发病有一定相关性;2)IL-21表达水平与NHL的分期、分组及有无结外浸润有关,治疗缓解后患者血清IL-21水平明显高于治疗前患者,提示IL-21的表达水平可能与NHL的预后有关。
[Abstract]:Aim: to detect the expression of interleukin-21 (IL-21) in serum of patients with non Hodgkin's lymphoma (NHL) and to explore the correlation between IL-21 and the pathogenesis and prognosis of NHL. Methods: from December 2015 to December 2016, 36 NHL patients treated in affiliated Hospital of Zunyi Medical College were selected as study subjects (20 newly diagnosed NHL patients and 16 NHL patients after chemotherapy) and 13 healthy persons as normal control group. The serum levels of IL-21 in NHL patients and controls were measured by enzyme linked immunosorbent assay (Elisa). To analyze the changes of serum IL-21 levels in NHL patients before and after treatment, and to explore the expression and clinical significance of serum IL-21 levels in NHL patients. Results the level of IL-21 in NHL patients (200.75 卤58.91ng / L) was significantly lower than that in controls (420.91 卤132.56ng / L), the difference was statistically significant (P0.05). The level of IL-21 in patients with stage III and stage IV was significantly lower than that in patients with stage I and II (223.87 卤35.36ngL). The level of serum IL-21 in patients with systemic symptoms (141.15 卤17.95 ng / L) was significantly lower than that in patients without systemic symptoms (208.46 卤33.50 ng / L) (P0.05), and the level of IL-21 in patients with extranodular infiltration (143.94 卤19.38 ng / L) was significantly lower than that in patients without nodule (P 0.05). There was no significant difference in serum IL-21 level (212.53 卤32.80ng / L) between the first diagnosed NHL patients (168.13 卤52.02ng / L) and those 鈮，

本文编号：2071666